Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DELMER MONTOYA MOTINO

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1740668383
CMS profile
8790236
Location
TUCSON, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$9,751.91

188 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,862.50 4
Food and Beverage $4,156.43 176
Education $403.16 6
Travel and Lodging $329.82 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Karyopharm Therapeutics Inc. $2,843.20 6
AstraZeneca Pharmaceuticals LP $1,788.68 13
Daiichi Sankyo Inc. $1,508.57 11
Regeneron Healthcare Solutions, Inc. $264.67 3
PFIZER INC. $235.02 14
Eisai Inc. $233.25 10
Celgene Corporation $221.40 17
Novartis Pharmaceuticals Corporation $177.97 12
Sumitomo Pharma America, Inc. $177.09 8
Gilead Sciences, Inc. $169.60 9
JAZZ PHARMACEUTICALS INC. $146.31 2
Incyte Corporation $135.66 3
Aveo Pharmaceuticals, Inc. $134.87 3
GENZYME CORPORATION $130.39 5
Amgen Inc. $121.83 1
Janssen Biotech, Inc. $120.86 3
ABBVIE INC. $116.91 5
Genmab U.S., Inc. $101.41 4
Merck Sharp & Dohme LLC $95.97 5
Takeda Pharmaceuticals U.S.A., Inc. $86.42 5
Rigel Pharmaceuticals, Inc. $81.94 6
ARRAY BIOPHARMA INC $77.95 4
Genentech USA, Inc. $66.36 3
BeiGene USA, Inc. $59.03 3
Lilly USA, LLC $57.36 3
Bayer Healthcare Pharmaceuticals Inc. $55.85 3
Exelixis Inc. $54.17 2
Janssen Pharmaceuticals, Inc $53.00 1
Alexion Pharmaceuticals, Inc. $50.51 2
GlaxoSmithKline, LLC. $50.48 3
Blueprint Medicines Corporation $44.07 2
SpringWorks Therapeutics, Inc. $40.06 2
Ipsen Biopharmaceuticals, Inc $36.88 2
Astellas Pharma US Inc $35.92 2
Mirati Therapeutics, Inc. $32.70 2
E.R. Squibb & Sons, L.L.C. $27.43 2
Pharmacosmos Therapeutics Inc. $21.32 1
Deciphera Pharmaceuticals Inc. $20.05 1
SERVIER PHARMACEUTICALS LLC $19.13 1
PUMA BIOTECHNOLOGY, INC. $15.34 1
Adaptive Biotechnologies Corporation $14.43 1
SOBI, INC $14.34 1
Stemline Therapeutics Inc. $13.51 1

Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DELMER MONTOYA MOTINO

NPI 1740668383 · CMS profile ID 8790236

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

TUCSON, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740668383?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DELMER MONTOYA MOTINO, NPI 1740668383, CMS profile ID 8790236. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740668383?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DELMER MONTOYA MOTINO, NPI 1740668383, CMS profile ID 8790236. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740668383?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DELMER MONTOYA MOTINO, NPI 1740668383, CMS profile ID 8790236, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1740668383?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

188 matching records · $9,751.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 188 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 188.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $23.1709/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141312611 CMS
Exelixis Inc. $24.3109/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138557125 CMS
Aveo Pharmaceuticals, Inc. $26.5808/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143476450 CMS
Eisai Inc. $24.7808/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110741431 CMS
PFIZER INC. $24.4508/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131348223 CMS
Daiichi Sankyo Inc. $120.4908/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089458920 CMS
Mirati Therapeutics, Inc. $15.6708/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117172084 CMS
Karyopharm Therapeutics Inc. $33.3108/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145529048 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.4508/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144963382 CMS
BeiGene USA, Inc. $20.6908/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120844985 CMS
Merck Sharp & Dohme LLC $19.9108/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141827796 CMS
Gilead Sciences, Inc. $27.6708/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133832956 CMS
E.R. Squibb & Sons, L.L.C. $14.2808/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101567691 CMS
Daiichi Sankyo Inc. $79.0008/01/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089458898 CMS
ARRAY BIOPHARMA INC $23.4607/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131335612 CMS
AstraZeneca Pharmaceuticals LP $22.6007/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104200815 CMS
PFIZER INC. $19.3307/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131897709 CMS
Celgene Corporation $17.0107/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101156644 CMS
GENZYME CORPORATION $31.6907/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139924353 CMS
Novartis Pharmaceuticals Corporation $32.2607/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086983318 CMS
E.R. Squibb & Sons, L.L.C. $13.1507/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101567669 CMS
Celgene Corporation $24.3307/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101156640 CMS
Eisai Inc. $19.0107/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110741427 CMS
Daiichi Sankyo Inc. $5.6907/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089458918 CMS
Celgene Corporation $19.6407/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101156642 CMS
Karyopharm Therapeutics Inc. $25.0707/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145529052 CMS
GlaxoSmithKline, LLC. $13.9307/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116701409 CMS
AstraZeneca Pharmaceuticals LP $27.6807/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104228575 CMS
Sumitomo Pharma America, Inc. $21.6806/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148892921 CMS
Rigel Pharmaceuticals, Inc. $19.0706/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145204612 CMS
PFIZER INC. $12.6206/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131675069 CMS
Merck Sharp & Dohme LLC $23.8306/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141573281 CMS
Eisai Inc. $22.0806/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110741421 CMS
Gilead Sciences, Inc. $25.4706/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133832954 CMS
Deciphera Pharmaceuticals Inc. $20.0506/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145874285 CMS
Sumitomo Pharma America, Inc. $13.6106/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148892919 CMS
Celgene Corporation $21.0206/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101156636 CMS
AstraZeneca Pharmaceuticals LP $22.1506/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105756225 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.0306/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144963380 CMS
GENZYME CORPORATION $21.7506/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139924331 CMS
PFIZER INC. $21.3106/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131326073 CMS
AstraZeneca Pharmaceuticals LP $14.7006/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104696272 CMS
Bayer Healthcare Pharmaceuticals Inc. $21.4006/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086113212 CMS
Incyte Corporation $89.9906/04/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141309007 CMS
Daiichi Sankyo Inc. $155.8606/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089458916 CMS
PFIZER INC. $20.0605/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131330922 CMS
Eisai Inc. $24.1205/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110741429 CMS
AstraZeneca Pharmaceuticals LP $34.7805/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104386825 CMS
Rigel Pharmaceuticals, Inc. $10.8905/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145198547 CMS
Blueprint Medicines Corporation $22.1805/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147444859 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $312.32 6
PY2021 $350.15 7
PY2022 $1,586.28 62
PY2023 $8,633.84 155
PY2024 $9,751.91 188
PY2025 $4,942.60 133

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $47,170.00 18
PY2023 Principal investigator $3,159.00 1
PY2022 Principal investigator $17,575.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184258015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 10/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184244883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184214566
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,000.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184214568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184214570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184214572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184214574
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184214576
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184214578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184214582
Principal investigator 1 Janssen Research & Development, LLC $1,997.00 03/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175404902
Principal investigator 1 Janssen Research & Development, LLC $1,820.00 03/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175405944
Principal investigator 1 Janssen Research & Development, LLC $2,244.00 03/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175406115
Principal investigator 1 Janssen Research & Development, LLC $1,115.00 03/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175407238
Principal investigator 1 BioNTech SE $97.00 01/01/2025 Non-covered Recipient Entity
Arizona Oncology Associates, PC
BNT327-01 No dispute reported 06/30/2026 1249017845
Principal investigator 1 BioNTech SE $97.00 01/01/2025 Non-covered Recipient Entity
Arizona Oncology Associates, PC
BNT327-01 No dispute reported 06/30/2026 1249017859